Karyopharm Therapeutics Announces Executive and Board Changes
Ticker: KPTI · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, compensation
Related Tickers: KPTI
TL;DR
Karyopharm shakes up exec team and board, updates pay. Big changes coming?
AI Summary
Karyopharm Therapeutics Inc. announced on September 5, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key executives.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty about future strategy and operational stability.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- September 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 85 Wells Avenue, 2nd Floor Newton, Massachusetts 02459 (address) — Principal Executive Offices
- (617) 658-0600 (phone_number) — Registrant's telephone number
FAQ
What specific roles have been affected by the executive departures?
The filing indicates the departure of 'certain officers' but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing states the election of directors but does not list their names in this initial section.
What are the key changes in compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers, but the specifics are not detailed in this initial summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 5, 2025.
What is the principal executive office address for Karyopharm Therapeutics Inc.?
The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-09-11 16:33:12
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- kpti-20250905.htm (8-K) — 64KB
- 0001503802-25-000006.txt ( ) — 175KB
- kpti-20250905.xsd (EX-101.SCH) — 30KB
- kpti-20250905_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the "Board") of Karyopharm Therapeutics Inc. (the "Company"), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza's resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Dr. Mirza is also resigning from his position as Chief Oncologist at Copenhagen University National Medical Center, effective October 1, 2025, to focus his professional efforts on his new executive role in industry. In connection with Dr. Mirza's resignation, the consulting agreement between the Company and Mirza Consulting, an entity wholly-owned by Dr. Mirza, for consulting and advisory services provided to the Company by Dr. Mirza was terminated effective as of September 8, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: September 11, 2025 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary